<DOC>
	<DOC>NCT00681720</DOC>
	<brief_summary>The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.</brief_summary>
	<brief_title>Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325</brief_title>
	<detailed_description />
	<mesh_term>Flumazenil</mesh_term>
	<criteria>Body Mass Index (BMI) of 1830 kg/m2 and weight of 60100 kg Clinically normal physical findings, medical history and laboratory values. Clinically significant illness or clinical relevant trauma within 2 weeks before the study start. Intake of another investigational drug or participation in a clinical study the past 12 weeks. Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>GABA receptors</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>PET</keyword>
	<keyword>phase I</keyword>
</DOC>